Why is Beta Drugs Ltd falling/rising?

As of 28-Jul, Beta Drugs Ltd is experiencing a decline in its stock price, currently at 1,686.50, reflecting a decrease of 23.65 points or 1.38%. The stock has underperformed its sector today by 1.46%. In terms of returns, the stock has shown a slight increase of 0.53% over the past week, but it has decreased by 5.04% over the last month. Year-to-date, the stock is down 11.63%, contrasting with a 4.38% gain in the benchmark index, Sensex. Although the stock has performed well over the longer term, with a 37.38% increase over the past year and an impressive 1,872.51% rise over five years, the recent performance indicates a struggle against broader market trends. Notably, there is rising investor participation, as evidenced by a 38.19% increase in delivery volume on July 25 compared to the five-day average, which may suggest some underlying interest despite the current price decline.
Broader Market Context: The Sensex has declined by 1.63% over the past week and 3.73% over the past month, indicating a challenging environment for stocks in general. While Beta Drugs Ltd has outperformed the benchmark in the short term, the overall negative sentiment in the market may be contributing to its recent price drop. The stock's liquidity remains adequate for trading, which could help mitigate some volatility. However, the stock's performance relative to the benchmark suggests that it is not immune to the broader market pressures affecting investor sentiment.